Morgan Stanley analyst Terence Flynn raised the firm’s price target on Amgen (AMGN) to $328 from $322 and keeps an Equal Weight rating on the shares. Amgen posted a Q4 beat and gave 2025 revenue and EPS guidance that bracketed consensus, which the firm views as a positive given questions ahead of the quarter, the analyst tells investors.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN: